Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/IIa study of IMM0306 injection combined with lenalidomide in CD20-positive B-cell non-Hodgkin lymphoma
CTR20231000Phase 2Active
- Sponsor
- ImmuneOnco
- Start
- Jun 2023
- Modality
- Small Molecules, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of IMM0306S, lenalidomide in mature B-cell lymphoma, follicular lymphoma (FL), marginal zone B-cell lymphoma (MZL), diffuse large B-cell lymphoma (DLBCL), sponsored by ImmuneOnco. Started Jun 2023; status: active.
02
Drugs
IMM0306Slenalidomide
03
Conditions
mature B-cell lymphomafollicular lymphoma (FL)marginal zone B-cell lymphoma (MZL)diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on CTR20231000.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20231000.